Why do 7 out of 10 new drug launches fall short of forecasts? The answer often hides in how market research is done—and where it falls flat. Many teams collect data but miss the story behind it. They study numbers but not the people behind the numbers. At KMK Consulting Inc., we saw this gap again and again. So, we built our work to fill it with clear answers. We work in the spaces that matter most—oncology, rare diseases, immunology, and more. They are full of complex patient paths, tough treatment plans, and deep emotional needs. Many research teams try to cover all this with a basic survey or simple study. But that doesn’t work here. We know how fast things change in these fields. A new study, a new approval, or a small shift in symptoms can change the whole plan. So, we stay close.

We read new updates daily. We learn from real stories. We speak to doctors, patients, and even carers. That’s how we spot real gaps before they grow. That’s how we help our clients see what’s ahead. This is how we make market research in the pharmaceutical industry work better. Along with that, a smart plan needs smart data. But many teams only look at one type—like a patient survey or doctor interview. We connect it all. We use primary data (what people tell us), secondary data (what we find from past studies), EMR (doctor records), claims (insurance info), and syndicated data (industry-wide sources). For example, a survey might say patients are happy. But EMR data may show many dropped treatments in three months. That’s a gap. A claim record may say one drug is used more, but our interviews reveal it’s only because there’s no better choice. At KMK Consulting Inc., we turn confusion into clarity, and doubt into direction with our smart market research in the pharmaceutical industry.